Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Sonelokimab in Moderate to Severe Chronic Plaque Psoriasis
NCT03384745Phase 2Completed
- Sponsor
- Bond Avillion 2 Development LP
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 7
01
Overview
A Phase 2 trial of sonelokimab in plaque psoriasis, sponsored by Bond Avillion 2 Development LP. Started Jul 2018; status: completed.
02
Drugs
sonelokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03384745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384745.